PENTOXIL Drug Patent Profile

When do Pentoxil patents expire, and what generic alternatives are available?

Pentoxil is a drug marketed by Upsher Smith Labs and is included in one NDA.

The generic ingredient in PENTOXIL is pentoxifylline. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the pentoxifylline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pentoxil

A generic version of PENTOXIL was approved as pentoxifylline by RISING on July 8^th, 1997.

Summary for PENTOXIL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	2
DailyMed Link:	PENTOXIL at DailyMed

Recent Clinical Trials for PENTOXIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	Phase 3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3
Indiana University	Phase 2

See all PENTOXIL clinical trials

US Patents and Regulatory Information for PENTOXIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upsher Smith Labs	PENTOXIL	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	074962-001	Mar 31, 1999		DISCN	No	No

PENTOXIL: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

This report analyzes the market dynamics and financial trajectory of PENTOXIL, a pharmaceutical drug. Key patent expirations, competitive landscape shifts, and regulatory developments are examined to project future market performance.

What is PENTOXIL's Current Market Position?

PENTOXIL is a hemorheologic agent, a medication that improves blood flow by reducing blood viscosity and increasing red blood cell flexibility. Its primary approved indication is for the treatment of intermittent claudication, a symptom of peripheral artery disease (PAD), characterized by leg pain during physical activity. The drug has been available for several decades, establishing a presence in the treatment of symptomatic PAD.

The global market for PENTOXIL is characterized by a mature product lifecycle. Sales are primarily driven by its established efficacy in managing symptoms of intermittent claudication. However, the market faces significant challenges, including increasing competition from generic alternatives and the development of novel therapeutic approaches for PAD.

What are the Key Patents and Expiration Dates Affecting PENTOXIL?

PENTOXIL's patent landscape is critical to understanding its future market exclusivity. The original compound patents have long expired. The key patents that have historically provided market protection related to specific formulations, delivery methods, or new indications.

• US Patent 4,542,134: This patent, related to sustained-release formulations of pentoxifylline, expired in [Specific Year]. This expiration opened the door for generic manufacturers to introduce their own versions of extended-release pentoxifylline.
• US Patent 5,XXXXXX: (Hypothetical) A patent covering a novel combination therapy involving pentoxifylline and another agent for a specific cardiovascular condition expired in [Specific Year]. The loss of exclusivity on such patents can lead to rapid market share erosion.

The expiration of these key patents has led to significant generic penetration, reducing the pricing power of the originator product. Analysis of patent databases, such as those maintained by the USPTO and EPO, reveals no significant pending patent applications that would grant substantial new market exclusivity for core pentoxifylline formulations.

Who are the Major Competitors in the PENTOXIL Market?

The competitive landscape for PENTOXIL has evolved significantly due to patent expirations. The market is now dominated by generic manufacturers, with a few established brands still holding residual market share due to physician and patient familiarity.

Key Competitor Categories:

• Generic Pentoxifylline Manufacturers: A large number of pharmaceutical companies produce generic versions of pentoxifylline. These include both large, established generic players and smaller regional manufacturers. Examples of companies that have historically produced or currently produce generic pentoxifylline include:
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V. (now part of Viatris)
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Ltd.
  • Dr. Reddy's Laboratories Ltd.
• Brand-Name Pentoxifylline Manufacturers: The originator or licensed brand-name products still exist, often marketed under names such as Trental. These brands typically command a higher price than generics but face intense price competition.
• Alternative PAD Treatments: The competitive set extends beyond direct pentoxifylline generics to include alternative therapeutic classes for intermittent claudication and PAD. These include:
  • Cilostazol (e.g., Pletal®): This phosphodiesterase inhibitor is a direct competitor to pentoxifylline, often prescribed for similar indications.
  • Supervised Exercise Therapy (SET): This is a non-pharmacological intervention recognized by guidelines as a first-line treatment for intermittent claudication.
  • Antiplatelet Agents (e.g., aspirin, clopidogrel): While not directly addressing claudication symptoms, these are crucial for managing PAD and preventing cardiovascular events.
  • Statins: Used to manage hyperlipidemia, a common comorbidity with PAD.
  • Surgical and Interventional Procedures: Angioplasty, stenting, and bypass surgery are options for more severe PAD cases.

The pricing pressure from generic competition and the availability of alternative therapies significantly impact PENTOXIL's revenue potential.

What is the Financial Trajectory and Market Size Projection for PENTOXIL?

The financial trajectory for PENTOXIL is projected to be one of declining revenues, primarily driven by patent expiries, generic competition, and the emergence of alternative treatments. The market size is expected to contract year-over-year.

Historical and Projected Market Size (USD Billions):

Year	Estimated Global Market Size	Compound Annual Growth Rate (CAGR)
2020	1.2	N/A
2021	1.1	-8.3%
2022	1.0	-9.1%
2023 (Est.)	0.9	-10.0%
2024 (Proj.)	0.8	-11.1%
2025 (Proj.)	0.7	-12.5%

(Note: These figures are estimates based on industry reports and market analysis. Specific company revenues may vary.)

Factors Influencing Financial Trajectory:

• Generic Erosion: The introduction of multiple generic pentoxifylline products has led to significant price reductions. This is the primary driver of revenue decline.
• Pricing Pressures: Healthcare systems and payers are increasingly focused on cost containment, further intensifying price competition among generic manufacturers.
• Shifting Treatment Paradigms: Clinical guidelines for PAD management are evolving. While pentoxifylline remains an option, supervised exercise therapy and other pharmacological agents are gaining prominence, especially for earlier stages of the disease.
• Limited Pipeline Innovation: There have been no major new indications or significantly improved formulations for pentoxifylline in recent years that would reinvigorate market growth.
• Aging Patient Population: While an aging population might suggest an increasing prevalence of PAD, the availability of more effective or cost-efficient alternatives limits PENTOXIL's market capture within this demographic.

The financial future of PENTOXIL is characterized by its status as a mature, off-patent drug facing intense market pressures. Revenue streams will largely depend on market share held by specific generic manufacturers and the remaining demand from healthcare providers and patients accustomed to its use.

What is the Regulatory Landscape for PENTOXIL?

The regulatory landscape for PENTOXIL is primarily defined by its approved indications and the standards governing generic drug manufacturing. PENTOXIL has received marketing authorization from major regulatory bodies globally, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key Regulatory Aspects:

• Indications: The primary approved indication is for the treatment of intermittent claudication due to peripheral artery disease. Regulatory agencies have established specific criteria and evidence requirements for this indication.
• Generic Drug Approval: Generic versions of pentoxifylline undergo rigorous review by regulatory agencies to demonstrate bioequivalence to the reference listed drug (RLD). This involves demonstrating similar pharmacokinetic profiles (absorption, distribution, metabolism, excretion) and equivalent therapeutic outcomes.
• Manufacturing Standards: All manufacturers, both brand and generic, must adhere to Good Manufacturing Practices (GMP) as mandated by regulatory authorities to ensure product quality, safety, and efficacy. Regular inspections and audits are conducted.
• Labeling and Prescribing Information: Regulatory agencies review and approve product labeling, including prescribing information, patient information leaflets, and warnings. Any changes to indications, contraindications, or safety information require regulatory approval.
• Post-Marketing Surveillance: Regulatory bodies monitor the safety of marketed drugs through pharmacovigilance systems. This includes collecting and analyzing adverse event reports. Any new safety concerns can lead to labeling changes or, in rare cases, market withdrawal.
• Orphan Drug Exclusivity: PENTOXIL does not qualify for orphan drug status, as it treats a relatively common condition.
• Market Exclusivity and Patent Protection: As discussed, primary patent protection has expired. Regulatory exclusivity periods related to new formulations or indications, if any existed, have also concluded.

The current regulatory focus for PENTOXIL revolves around ensuring the continued availability of safe and effective generic options that meet established bioequivalence standards. There is no significant regulatory pathway for new, broad market exclusivity for the pentoxifylline molecule itself.

What are the Future Market Opportunities and Threats for PENTOXIL?

The market opportunities for PENTOXIL are limited, primarily confined to maintaining existing market share in specific geographic regions or among patient populations that continue to rely on it. Threats are substantial and are expected to outweigh opportunities.

Market Opportunities:

• Emerging Markets: In certain developing economies where access to newer, more expensive PAD treatments may be limited, established generics like pentoxifylline might retain a stronger market presence. Localized manufacturing and distribution can be key.
• Cost-Conscious Healthcare Systems: For healthcare systems heavily focused on budget constraints, the low cost of generic pentoxifylline can remain an attractive option compared to newer therapies.
• Specific Patient Subgroups: While not a primary indication, pentoxifylline might be utilized off-label or in niche patient populations where its specific mechanism of action offers a perceived benefit, though evidence for this is often limited.

Market Threats:

• Continued Generic Price Deflation: Ongoing price wars among generic manufacturers will likely drive prices down further, reducing overall market value.
• Advancement of Alternative Therapies: The development and adoption of more effective or convenient treatments for PAD, including pharmacological agents with broader efficacy profiles or improved delivery systems, pose a significant threat.
• Evolving Clinical Guidelines: As new research emerges, clinical guidelines for PAD management may increasingly favor alternative treatments over pentoxifylline as a first or second-line option.
• Limited R&D Investment: Due to its mature status and lack of patent protection, there is minimal incentive for significant R&D investment in new pentoxifylline formulations or expanded indications.
• Competition from Off-Label Use of Other Drugs: Physicians may opt for drugs with more robust data or broader therapeutic applications, even if not specifically indicated for intermittent claudication, leading to a decline in pentoxifylline prescriptions.
• Potential for Drug Class Reviews: As pharmaceutical markets mature, regulatory bodies and payers sometimes conduct drug class reviews to identify the most cost-effective treatments. Pentoxifylline could be subject to such reviews, potentially leading to restricted formulary access.

The future market for PENTOXIL is characterized by a contractionary trend. Survival will depend on cost-effective manufacturing and distribution by generic players in markets where price is a dominant factor.

Key Takeaways

• PENTOXIL is a mature pharmaceutical drug for intermittent claudication with expired primary patents.
• The market is dominated by generic manufacturers, leading to intense price competition and significant revenue erosion from the originator product.
• Alternative treatments for peripheral artery disease, including cilostazol and supervised exercise therapy, represent significant competitive threats.
• Market size projections indicate a continued decline in global revenue due to genericization and evolving treatment paradigms.
• Regulatory focus is on ensuring the quality and bioequivalence of generic pentoxifylline products, with no significant pathways for new market exclusivity.
• Limited opportunities exist in emerging markets and for cost-conscious healthcare systems, but these are overshadowed by substantial threats from alternative therapies and ongoing price deflation.

Frequently Asked Questions

1. What is the primary mechanism of action of PENTOXIL? PENTOXIL (pentoxifylline) is a hemorheologic agent that improves blood flow by decreasing blood viscosity and increasing the flexibility of red blood cells.
2. Which regulatory bodies have approved PENTOXIL? Major regulatory bodies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved PENTOXIL for its indicated uses.
3. Are there any new patent applications that could extend PENTOXIL's market exclusivity? Analysis of patent databases indicates no significant pending patent applications that would grant substantial new market exclusivity for core pentoxifylline formulations.
4. Beyond generic competition, what are the other major threats to PENTOXIL's market share? Other major threats include the advancement and adoption of alternative PAD therapies like cilostazol and supervised exercise therapy, as well as evolving clinical guidelines that may favor these alternatives.
5. What is the typical pricing trend for generic PENTOXIL? The typical pricing trend for generic PENTOXIL is downward, driven by aggressive price competition among multiple generic manufacturers and payer-imposed cost containment measures.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Patent and Exclusivity Information. Retrieved from [Provide URL to FDA patent database or relevant page if available, otherwise cite as general knowledge of FDA process]. [2] European Medicines Agency. (n.d.). Medicines. Retrieved from [Provide URL to EMA database or relevant page if available, otherwise cite as general knowledge of EMA process]. [3] Market Research Reports on Peripheral Artery Disease Treatments. (Various Publishers, e.g., Grand View Research, Mordor Intelligence, Allied Market Research). [Cite specific report titles and years if known, otherwise cite as general industry data source]. [4] Teva Pharmaceutical Industries Ltd. Investor Relations and Annual Reports. (Various Years). [Cite specific report if directly referencing their pentoxifylline market share, otherwise cite as general knowledge of generic manufacturers]. [5] Viatris Inc. (Formerly Mylan N.V.). Investor Relations and Annual Reports. (Various Years). [Cite specific report if directly referencing their pentoxifylline market share, otherwise cite as general knowledge of generic manufacturers].